A C B Marini, D R S Perez, J A Fleuri, G D Pimentel
{"title":"SARC-F Is Better Correlated with Muscle Function Indicators than Muscle Mass in Older Hemodialysis Patients.","authors":"A C B Marini, D R S Perez, J A Fleuri, G D Pimentel","doi":"10.1007/s12603-020-1426-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sarcopenia can be characterized by European Consensus for Sarcopenia (EWGSOP2) criteria, but it methods are not easily accessible. Likewise, the Strength, Assistance with walking, Rise from a Chair, Climb stairs and Falls (SARC-F) has been proposed.</p><p><strong>Objective: </strong>The aim of this study was i) to evaluate the prevalence for risk sarcopenia and ii) to correlate the SARC-F with components of the EWGSOP2 consensus in hemodialysis (HD) patients.</p><p><strong>Measurements: </strong>This cross-sectional study enrolled ninety-five (male n= 59; 62%) HD older patients. Sarcopenia risk was assessed using the SARC-F, which ≥4 score indicates sarcopenia risk. Sarcopenia was confirmed through of the EWGSOP2 consensus, including the handgrip strength (HGS <27kg for men and <16kg for women) using the dynamometer, muscle mass through appendicular muscle mass (ASMI/m2 <7.0 kg/m2 for men and 5.5 kg/m2 for women) using the bioimpedance electrical, and physical performance through of gait speed (GS <0.8 m/s).</p><p><strong>Results: </strong>From 95 patients, n=21(22%) presented sarcopenia risk. SARC-F ≥4 group are older (64.9±13.9 vs. 56.9±14.6 y, p= 0.028), presented lower ASMI (7.4±1.2 vs. 8.3±1.8 kg/m2, p=0.033), HGS (20.5±5.7 vs. 27.2±10.2 kg, p=0.005), and GS (0.5±0.1 vs. 0.7±0.1 m/s, p=0.001) than SARC-F<4 group. SARC-F score was negatively correlated with EWGSOP2 components: ASMI x SARC-F (r=-0.27, p=0.007), HGS x SARC-F (r=-0.35, p=0.0005), and GS x SARC-F (r=-0.47, p<0.0001). Although, no difference of number of patients with low or normal ASMI values was found, 62% and 95% of SARC-F≥4 group patients presented low HGS and gait speed, respectively.</p><p><strong>Conclusions: </strong>In older HD patients, 22% presented sarcopenia risk. In addition, SARC-F is better correlated with muscle function indicators (HGS and gait speed) than muscle mass.</p>","PeriodicalId":501202,"journal":{"name":"The Journal of Nutrition, Health & Aging","volume":" ","pages":"999-1002"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12280642/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nutrition, Health & Aging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12603-020-1426-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Sarcopenia can be characterized by European Consensus for Sarcopenia (EWGSOP2) criteria, but it methods are not easily accessible. Likewise, the Strength, Assistance with walking, Rise from a Chair, Climb stairs and Falls (SARC-F) has been proposed.
Objective: The aim of this study was i) to evaluate the prevalence for risk sarcopenia and ii) to correlate the SARC-F with components of the EWGSOP2 consensus in hemodialysis (HD) patients.
Measurements: This cross-sectional study enrolled ninety-five (male n= 59; 62%) HD older patients. Sarcopenia risk was assessed using the SARC-F, which ≥4 score indicates sarcopenia risk. Sarcopenia was confirmed through of the EWGSOP2 consensus, including the handgrip strength (HGS <27kg for men and <16kg for women) using the dynamometer, muscle mass through appendicular muscle mass (ASMI/m2 <7.0 kg/m2 for men and 5.5 kg/m2 for women) using the bioimpedance electrical, and physical performance through of gait speed (GS <0.8 m/s).
Results: From 95 patients, n=21(22%) presented sarcopenia risk. SARC-F ≥4 group are older (64.9±13.9 vs. 56.9±14.6 y, p= 0.028), presented lower ASMI (7.4±1.2 vs. 8.3±1.8 kg/m2, p=0.033), HGS (20.5±5.7 vs. 27.2±10.2 kg, p=0.005), and GS (0.5±0.1 vs. 0.7±0.1 m/s, p=0.001) than SARC-F<4 group. SARC-F score was negatively correlated with EWGSOP2 components: ASMI x SARC-F (r=-0.27, p=0.007), HGS x SARC-F (r=-0.35, p=0.0005), and GS x SARC-F (r=-0.47, p<0.0001). Although, no difference of number of patients with low or normal ASMI values was found, 62% and 95% of SARC-F≥4 group patients presented low HGS and gait speed, respectively.
Conclusions: In older HD patients, 22% presented sarcopenia risk. In addition, SARC-F is better correlated with muscle function indicators (HGS and gait speed) than muscle mass.
背景:骨骼肌减少症可以通过欧洲共识骨骼肌减少症(EWGSOP2)标准来表征,但其方法不容易获得。同样,力量、行走辅助、从椅子上站起来、爬楼梯和跌倒(SARC-F)也被提出。目的:本研究的目的是1)评估血透(HD)患者高危肌少症的患病率,2)将SARC-F与EWGSOP2共识的组成部分联系起来。测量方法:本横断面研究纳入95人(男性n= 59;62%)老年HD患者。采用SARC-F评估骨骼肌减少风险,评分≥4分为骨骼肌减少风险。通过EWGSOP2共识确认肌肉减少症,包括握力(HGS)结果:95例患者中,n=21(22%)存在肌肉减少症风险。SARC-F≥4组患者年龄较大(64.9±13.9 vs. 56.9±14.6 y, p= 0.028), ASMI(7.4±1.2 vs. 8.3±1.8 kg/m2, p=0.033)、HGS(20.5±5.7 vs. 27.2±10.2 kg, p=0.005)、GS(0.5±0.1 vs. 0.7±0.1 m/s, p=0.001)均低于SARC-F组。此外,SARC-F与肌肉功能指标(HGS和步态速度)的相关性优于肌肉质量。